ストックスクリーナーアプリを入手
17.28
1.37%
-0.24
プレマーケット:
16.65
-0.63
-3.65%
前日終値:
$17.52
開ける：
$17.54
24時間の取引高:
2.44M
Relative Volume:
1.09
時価総額：
$2.40B
収益：
$715.22M
当期純損益:
$-250.10M
株価収益率:
-8.5123
EPS:
-2.03
ネットキャッシュフロー:
$-205.58M
1週間 パフォーマンス:
-9.62%
1か月 パフォーマンス:
-11.02%
6か月 パフォーマンス:
-38.83%
1年 パフォーマンス:
-59.82%
1日の値動き範囲:
$17.16
$17.64
1週間の範囲:
$16.65
$19.32
52週間の値動き範囲:
$16.65
$43.99
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
名前
Apellis Pharmaceuticals Inc
セクター
電話
617-977-5700
住所
100 FIFTH AVENUE, WALTHAM, KY
APLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
17.28 | 2.40B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-17 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-21 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-16 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Neutral |
| 2024-02-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-02 | 開始されました | Mizuho | Neutral |
| 2023-10-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-15 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 繰り返されました | Citigroup | Buy |
| 2023-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-08-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-17 | 再開されました | Stifel | Buy |
| 2022-04-14 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-09-10 | 繰り返されました | Credit Suisse | Neutral |
| 2021-09-10 | 繰り返されました | Needham | Buy |
| 2021-09-10 | 繰り返されました | Oppenheimer | Outperform |
| 2021-09-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-08-19 | 開始されました | Jefferies | Buy |
| 2021-08-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2020-11-19 | 開始されました | Needham | Buy |
| 2020-09-01 | 開始されました | Stifel | Buy |
| 2020-07-20 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-04-01 | 開始されました | Raymond James | Strong Buy |
| 2020-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-11 | アップグレード | Wedbush | Underperform → Neutral |
| 2020-01-07 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-12-19 | 開始されました | BofA/Merrill | Buy |
| 2019-11-22 | 開始されました | Wedbush | Underperform |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-08-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-07-30 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-04-12 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Mizuho Securities Adjusts Apellis Pharmaceuticals Price Target to $20 From $30, Maintains Neutral Rating - marketscreener.com
APLS: Apellis Pharmaceuticals Stock Downgraded by B of A Securit - GuruFocus
Raymond James Downgrades Apellis Pharmaceuticals (BIT:1APLS) - Nasdaq
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Pri - GuruFocus
Sector Update: Health Care - marketscreener.com
Apellis Pharmaceuticals Stumbles Over Funding And Sales Hurdles - Finimize
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Price Target Cut | APLS Stock News - GuruFocus
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down - MSN
Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’ - Investing.com Canada
Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back? - Insider Monkey
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Targ - GuruFocus
Apellis (APLS) Faces Downgrade Amid Sales Volatility Concerns | - GuruFocus
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers - simplywall.st
BofA Adjusts Apellis (APLS) Rating to Neutral, Lowers Price Target | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - MSN
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates - MSN
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capi - GuruFocus
Apellis Pharmaceuticals (APLS) Analyst Rating Update by RBC Capital | APLS Stock News - GuruFocus
Apellis (APLS) Price Target Reduced by Scotiabank Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS) Price Target Lowered by Scotiabank | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (APLS): Wells Fargo Lowers Price Target to $26 | APLS Stock News - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2025 Earnings Call Transcript - Insider Monkey
Apellis Pharmaceuticals (APLS) Target Price Lowered by Analyst | APLS Stock News - GuruFocus
Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks - TipRanks
Apellis Pharmaceuticals (APLS) Price Target Reduced by Analyst | APLS Stock News - GuruFocus
Apellis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ... - Yahoo Finance
Fierce Biotech Layoff Tracker 2025: Insitro shrinks team by 22%; Shape ships out staff - Fierce Biotech
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - Barchart.com
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Why Apellis Pharmaceuticals (APLS) Stock is Declining - GuruFocus
Why Apellis Pharmaceuticals Wilted on Wednesday - MSN
APLS: Apellis Pharmaceuticals Maintains Buy Rating Amid Price Target Cut | APLS Stock News - GuruFocus
Transcript : Apellis Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Apellis Pharmaceuticals misses Q1 2025 estimates By Investing.com - Investing.com Nigeria
Earnings call transcript: Apellis Pharmaceuticals misses Q1 2025 estimates - Investing.com
Apellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issues By Investing.com - Investing.com Nigeria
Apellis Pharmaceuticals stock tumbles on Q1 revenue miss, inventory issues - Investing.com
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results - The Manila Times
Apellis (APLS) Sees Q1 Revenue Miss as Strategic Growth Continues | APLS Stock News - GuruFocus
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BRIEF-Apellis Pharmaceuticals Q1 Basic EPS USD -0.74 - TradingView
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - TradingView
Apellis Pharmaceuticals Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - Louisiana First News
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Apellis Pharmaceuticals Inc (APLS) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):